Фармакокинетическая и биофармацевтическая оценка качества твердых лекарственных форм методами in vitro и in vivo
Диссертация
Основные результаты исследования доложены на Всероссийской научно-практической конференции «Клинические протоколы в общей врачебной практике» (Санкт-Петербург, октябрь, 2007) — на конференции молодых ученых, посвященной 250-летию ММА им. И. М. Сеченова (Москва, май, 2008) — на секции № 1 Ученого совета ФГУ «Научный центр экспертизы средств медицинского применения» Росздравнадзора (Москва, апрель… Читать ещё >
Содержание
- ГЛАВА 1. Обзор литературы
- 1. 1. Современные подходы к оценке биодоступности и биоэквивалентности лекарственных средств
- 1. 2. Влияние физико-химических характеристик кристаллической субстанции на фармакокинетику лекарственного средства
- 1. 3. Особенности фармакокинетики лекарственных форм с модифицированным высвобождением
- Экспериментальная часть (материалы собственных исследований)
- ГЛАВА 2. Материалы и методы исследования
- ГЛАВА 3. Изучение влияния различных факторов на высвобождение действующего вещества из твердых дозированных форм
- 3. 1. Влияние физико-химических параметров субстанции на высвобождение/растворение диклофенака из таблеток Диклофенак в условиях in vitro
- 3. 2. Влияние состава вспомогательных веществ на процессы растворения и всасывания фенкарола из таблеток Фенкарол
- 3. 3. Изучение кинетики растворения атенолола из фармацевтически эквивалентных ЛФ
- ГЛАВА 4. Теоретические и практические основы проведения исследований биоэквивалентности препаратов нифедипина
- 4. 1. Исследование высвобождения препаратов нифедипина in vitro
- 4. 2. Изучение биоэквивалентности препаратов нифедипина
- 4. 2. 1. Выбор и рандомизация волонтеров
- 4. 2. 2. Тактика проведения исследования
- 4. 2. 3. Методика определения нифедипина в плазме крови
- 4. 2. 4. Расчет фармакокинетических параметров и статистическая обработка полученных результатов
- 4. 2. 5. Динамика концентрации нифедипина после приема препаратов Карин-фер и Коринфар
- 4. 2. 6. Фармакокинетика нифедипина после приема препаратов Карин-фер и Коринфар
- 4. 2. 7. Относительная биодоступность и биоэквивалентность препаратов Карин-фер и Коринфар
- 5. 1. Исследование высвобождения препаратов омепразола in vitro
- 5. 2. Изучение биоэквивалентности препаратов омепразола
- 5. 2. 1. Выбор и рандомизация волонтеров
- 5. 2. 2. Тактика проведения исследования
- 5. 2. 3. Методика определения омепразола в плазме крови
- 5. 2. 4. Расчет фармакокинетических параметров и статистическая обработка полученных результатов
- 5. 2. 5. Динамика концентрации омепразола после приема препаратов Омез и Лосек
- 5. 2. 6. Фармакокинетика омепразола после приема препаратов Омез и Лосек
- 5. 2. 7. Относительная биодоступность и биоэквивалентность препаратов Омез и Лосек
Список литературы
- Арзамасцев А.П., Дорофеев B.JL Эквивалентность воспроизведенных лекарственных средств: фармацевтические аспекты. /Ведомости НЦЭСМП. 2007.- № 1.
- Арзамасцев А.П., Садчикова Н. П., Лутцева Т. Ю. Название. //Хим.-фарм. журн. 2003. — Т. 37. — № 1. — С.39 — 45.
- Государственный стандарт качества лекарственных средств. Общая фармакопейная статья «Растворение» М., 2004. — 20 с.
- Леонова М.В. Пероральные лекарственные формы с модифицированным высвобождением. //Фарматека. 2006. -№ 11.- С.32−37.
- Лукьянова М.С., Иванова Р. А., Куриленко В. М. и др. Сравнительная биодоступность двух таблетированных форм циннаризина. //3-я Всесоюзная конф. по фармакокинетике. Москва. — 1991. — С. 162.
- Мешковский А.П. Обеспечение качества фармацевтических субстанций за рубежом сегодня и завтра. //Фарматека. — 2000. — № 1(37). — С.29−34.
- Проблема калибровки приборов для испытания «Растворение». /А.П.Арзамасцев, Н. П. Садчикова, Т. Ю. Лутцева, Г. В. Раменская, и др. //Фармация. 2003. — Т.37. — № 10. — С.12−17.
- Проведение качественных исследований биоэквивалентности лекарственных средств. Метод, указания МЗСР РФ. Москва, 2004. — 43с.
- Сереброва С.Ю., Давыдова К. С., Кукес В. Г. Оценка относительной биодоступности и клинической эффективности омепразола (Гастрозо-ла). //Клин. фарм. и терапия 2001. — № 10(1). — С.12−14.
- Чижова Д.А., Бунятян Н. Д. Оценка эффективности и безопасности лекарственных средств в опытах in vitro. //Сб. докладов Всероссийской научно-практической конференции «Клинические протоколы в общей врачебной практике». СПб., 2007. — С.182−186.
- Чижова Д.А., Бунятян Н. Д. Оценка скорости и степени высвобождениялекарственных средств в опытах in vitro. //Аптечный бизнес. 2009. — № 2. — С.26−27.
- Чижова Д.А., Бунятян Н. Д., Василенко Г. Ф. Современные подходы к изучению высвобождения лекарственных веществ из твердых дозированных лекарственных форм в условиях in vitro и in vivo. // Фармация. -2008. № 2. — С.50−52.
- Чистяков В.В., Никифорова О. В., Давыдова К. С. Исследование биоэквивалентности гастрозола. //Ремедиум. — 2000. — № 5- С. 64.
- Abdelbary GA, Tadros MI. Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer. //Eur J Pharm Biopharm.-2008.-69(3).-P. 1019−1028.
- Abdullah MD, Bepary S, Rouf AS. Report: in vitro dissolution studies of different brands of sustained release diclofenac sodium matrix tablet available in Bangladesh. //Pak J Pharm Sci.-2008.-21(l).-P.70−77.
- Adjei A., Garren J. Pulmonary delivary of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. //Pharm. Res. 1990. — Vol.7. — № 6. — P.565−569.
- Amantea M.A., Narang P.K. Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography. //J.Chromatogr.-l988.-V.426.-P.216−222.
- Amidon GL, Lennernas H, Shah VP, and Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability.// Pharm. Research.-1995.-Vol. 12-№ 3.
- Analytical, biopharmaceutical and regulatory evaluation of topical testosterone preparations. /Baert B, Annavarapu S, Burvenich C, De Spiegeleer B. //Eur J Pharm Biopharm.- 2009−72(1)-P.275−281.
- A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. /Rostami-Hodjegan A, Shiran MR, Tucker GT, Conway BR, et al. //Drug Dev Ind Pharm.- 2002.-28(5).-P.533−543.
- A novel pH-dependent gradient-release delivery system for nitrendipine: I. Manufacturing, evaluation in vitro and bioavailability in healthy dogs. /Yang M, Cui F, You B, You J, et al. //J Control Release.- 2004.-98(2).-P.219−229.
- Aoki I., Okumura M., Yashiki T. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. //J.Chromatogr.-1991 .-V.571 (1 -2)-P.283−290.
- Application of linear mixed effects models to the evaluation of dissolution profiles. /Adams E, Coomans D, Smeyers-Verbeke J, Massart DL. //Int J Pharm.- 2001 .-226(1 -2).-P. 107−125.
- Atkinson R.M., Bedford C, Child K.J., Tomich E.G. The effect of griseo-fiilvin particle size on blood levels in man. //Antibiot. Chemother. 1962. -Vol.12. — P.232−238.
- Baldi F. Lansoprazole oro-dispersible tablet: pharmacokinetic and therapeutic use in acid-related disorders. //Drugs. 2005. — № 65(10). — P.1419−1426.
- Banerjee P. S., Robinson J.R. Novel drug delivery systems: an overview of their impact on clinical pharmacokinetic studies. //Clin.Pharmacokinet-1991.-20(1):1−14.
- Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. /Schaltenbrand R, Huber R, et al. Hint J Clin Pharmacol Ther. -2001.-39(10).-P.453−459.
- Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions, /de Campos DR, Vieira NR, Bernasconi G, Barros FA, et al. //Arzneimittelforschung.- 2007.-57(6).-P.309−314.
- Bioequivalence of two oral ciprofloxacin tablets formulations. /Cuadrado A, Gascon AR, Solinis MA, Ramirez E, et al. //Int J Clin Pharmacol Ther.-2004.-42(6).-P.33 6−341.
- Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. /Cheng CL, Yu LX, Lee HL, et al. //Eur J Pharm Sci.- 2004.-22(4).-P.297−304.
- Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). /Kalantzi L, Reppas C, Dressman JB, et al. //J Pharm Sci.-2006.-95(l).-P.4−14.
- Bolton S. Correlation in pharmaceutical statistics: practical and clinical applications, 2nd ed., Marcel Dekker Inc., New York, 1991.-P.211−245.
- British Pharmacopoeia, 2005.
- Brockmeier D, von Hattingberg HM. In vitro /in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. //Arzneimittelforschung.-1982.-32(3).-P.248−251.
- Cho HY, Kang HA, Lee YB. Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers. //Int J Clin Pharmacol Ther.- 2006.-44(8).-P.386−392.
- Chow SC, Ki FY. Statistical comparison between dissolution profiles ofdrug products. //J Biopharm Stat. -1997.-7(2).-P.241−258.
- Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. /Waller ES, Crismon ML, Smith RV, et al. //Biopharm Drug Dispos.- 1988.-9(2).-P.211−218.
- Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles. /Martinez MN, Kawa-lek JC, Howard KD, Ward JL, et al. //J Vet Pharmacol Ther.-2006.-29(6).-P.459−467.
- Comparison of dissolution profiles of Ibuprofen pellets. /Costa FO, Sousa JJ, Pais AA, Formosinho SJ. //J Control Release. -2003.-89(2).-P.l99−212.
- Comparison of dissolution profiles for sustained release resinates of BCS class I drugs using USP apparatus 2 and 4: a technical note. /Prabhu NB, Marathe AS, Jain S, Singh PP, et al. //AAPS PharmSciTech.- 2008.-9(3).-P.769−773.
- Correlation between in vitro dissolution profiles from enteric-coated dosage forms and in vivo absorption in rats for high-solubility and high-permeability model drugs. /Sakuma S, Ogura R, Masaoka Y, Kataoka M, et al. //J.Pharm.Sci.-2009.- Mar 12.
- Corrigan OI, Devlin Y, Butler J. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Hint J Pharm.- 2003.-254(2).-147−154.
- Desai D, Kothari S, Huang M. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules. /Ant J Pharm.-2008.-3 54(l-2).-P.77−81.
- Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. /He W, Fan LF, Du Q, Xiang B, et al. //Chem. Pharm. Bull (Tokyo).- 2009.-57(2).-P. 122−128.
- Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. /Tanaka
- N, Imai К, Okimoto К, Ueda S, et al. //Control Release.- 2005.-108(2−3).-P.386−395.
- Development of tablets for controlled joint release of nifedipine and atenolol. /Iglesias R, Taboada C, Souto C, et al. //Drug Dev Ind Pharm.-1998.-24(9).-P.835−840.
- Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets. /Breier AR, Paim CS, Steppe M, Schapoval EE. //J Pharm Pharm Sci. -2005.-8(2).-P.289−298.
- Devrim B, Canefe K. Preparation and evaluation of modified release ibupro-fen microspheres with acrylic polymers (Eudragit) by quasi-emulsion solvent diffusion method: effect of variables. //Acta Pol Pharm.- 2006.-63(6).-P.-521−534.
- Diclofenac sodium multisource prolonged release tablets—a comparative study on the dissolution profiles. /Bertocchi P, Antoniella E, Valvo L, et al. //J Pharm Biomed Anal.- 2005.-37(4).-P.679−685.
- Dissolution kinetics of carboxylic acids II: effect of buffers. /Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. //J Pharm Sci.-1981.-70(l).-22−32.
- Dominguez A, Medina R, Hurtado M. Bioequivalence study of paracetamol tablets: in vitro-in vivo correlation. //Drug Dev Ind Pharm.- 2000.-26(8).-P.821−828.
- Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: Immediate Release dosage forms/ Pharmaceutical Research, Vol 15. 1998. — № 1.
- Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. /Okumu A, DiMaso M, Loben-berg R. //Pharm Res.- 2008.-25(12).-P.2778−2785.
- Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. /Konno H, Handa T, Alonzo DE, Taylor LS. //Eur J Pharm Biopharm.-2008.-70(2).-P.493−499.
- Emami J. In vitro-in vivo correlation: From theory to applications. // Pharm.
- Pharmaceut. Sci. -2006.-9(2)-P.169−189.
- European Pharmacopoeia 5 th ed., 2005.
- Evaluation of in vitro dissolution and in vivo absorption for two different film-coated pellets of clarithromycin. /Zhang XR, Chen XY, Hu LD, et al. //Arch Pharm Res.- 2005.-28(8).-P.977−982.
- Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. /Rekhi GS, Eddington ND, Fossler MJ, et al. //Pharm Dev Technol.-1997.-2(l).-P.l 1−24.
- Faassen F, Vromans H. Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. //Clin Pharmacokinet.- 2004.-43(15).-P.1117−1126.
- Fassihi RA, Ritschel WA. Multiple-layer, direct-compression, controlled-release system: in vitro and in vivo evaluation. //J Pharm Sci.- 1993.-82(7).-P.750−754.
- Gen? L, Jalvand E. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design. //Drug Dev Ind Pharm.-2008.-34(8).-P.903−910.
- Gohel MC, Amin AF. Formulation design and optimization of modified-release microspheres of diclofenac sodium. //Drug Dev Ind Pharm.-1999.-25(2).-P.247−251.
- Gordon MS, Chowhan Z. In vivo/in vitro correlations for four differently dissolving ketorolac tablets. //Biopharm Drug Dispos.-1996.-17(6).-P.481−492.
- Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. FDA, CDER, 1997.
- Guidance for industry: extended release oral dosage forms: development, evaluation and application of an in vitro/in vivo correlation. FDA, CDER, 1997.
- Guidance for industry: Waiver of in vivo bioavailability and bioequivalencestudies for immediate-release solid oral dosage forms based on a Biophar-maceutics Classification System. FDA, CDER, 2000.
- Hamed E, Sakr A. Application of multiple response optimization technique to extended release formulations design. //J Control Release.-2001.-73(2−3).-P.329−338.
- Hassoun M., Dorion P., et al. Drug substance crystallization in pharmaceutical development: key stage for the control of physical properties. STP Phar-ma Pratiques, 2003.
- Humbert H, Cabiac MD, Bosshardt H. In vitro-in vivo correlation of a modi-fied-release oral form of ketotifen: in vitro dissolution rate specification. //J Pharm Sci. -1994.-83(2).-P.131−136.
- Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices. /Papageorgiou GZ, Papadimitriou S, Karavas E, Georgarakis E., et al. //Curr.Drug Deliv.-2009.-6(l).-P. 101−112.
- International harmonization of generic drugs: in vitro dissolution tests for Japanese and American generic tablets. /Otsuka M, Tomita H, Otsuka K, Kamae I, et al. //Biomed Mater Eng.- 2006.-16(2).-P. 129−135.
- International Pharmacopoeia, 4th ed., 2006.
- Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. /Krishnaswami S, Hochhaus G, Mollmann H, Barth J. //Int J Clin Pharmacol Ther.- 2005.-43(3).-P. 117−122.
- In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. /Hayashi T, Kanbe H, Okada M, et al. //Int J Pharm.-2007.-341(l-2).-P. 105−113.
- In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. /Wang Y, Lee L, Somma R, Thompson G, Bakhtiar R, et al. //Biopharm Drug Dispos. -2004.-25(2).-P.91−98.
- In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble ci-lostazol. /Jinno J, Kamada N, Miyake M, Yamada K, et al. //J Control Re-lease.-2008.-130(l).-P.29−37.
- In vitro-in vivo relationship of oral extended-release dosage forms. /Liu FY, Sambol NC, Giannini RP, Liu CY. //Pharm Res. -1996.-13(10).-P.1501−1506.
- Japanese Pharmacopoeia, 14th ed., 2001.
- Katz В., Rosenberg A., Frishman W.H. Controlled-release drug delivery systems in cardiovascular medicine. //Am. Heart J.-1995.-129(2):359−368.
- Kellaway I.W. Scientific rationale and clinical implications of sustained-release formulations.//Br.J.Clin.Pract.-1988.-42(Suppl.60).-P.9−13.
- Khalafalla N. In vitro dissolution of different brands of griseofulvin tablets. //Pharmazie.- 1980.-35(9).-P.555−558.
- KramI M., Dubic J., Gaudry R. Gastrointestinal absorption of griseofulvin. II. Influence of particle size in man. //Antibiot. Chemother., Vol.12, p.239−242 (1962).
- Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series. /Kortejarvi H, Malkki J, Marvola M, et al. //J Pharm Sci. -2006.-95(7).-P. 1595−1605.
- Lobenberg R, Kramer J, Shah VP, Amidon GL. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Dissolution Behavior of Gliben-clamide. //Pharm.Research.-2000.-Vol. 17.-№ 4.
- Mclnnes G.T., Asbury M.J., Ramsay L.E., Shelton J.R. Effect of microniza-tion on bioavailability and pharmacologic activity of spironolactone. //J.Clin.Pharmacol. Vol.22. — P.410−417.
- Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. /Polli JE, Rekhi GS, Augs-burger LL, Shah VP. //J Pharm Sci. -1997.-86(6).-P.690−700.
- Moore J.W., Flanner H.H. Mathematical comparison of dissolution profiles. //Pharm.Tech.-1996.- 20(6)-P.64−74.
- Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. — WHO Technical Report Series, № 937, 2006.
- Nimmerfall F., Rosenthaller J. Dependence of area under the curve on pro-quazone particle size and in vitro dissolution rate. //J. Pharm. Sci. 1980. -Vol.69. — № 5.- P.605−607.
- Novel approach for determination of correlation between in vivo and in vitro dissolution using the optimization technique. /Ishii K, Saitou Y, Yamada R, Itai S, Nemoto M. //Chem Pharm Bull (Tokyo).-1996.-44(8).-P.1550−1555.
- Oral sustained delivery of atenolol from floating matrix tablets-formulation and in vitro evaluation. /Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. //Drug Dev Ind Pharm.-2005.-3 l (4−5).-P.367−374.
- Pharmacokinetic analysis of single- or multiple-dose plasma drug concentration data with a microcomputer using multi-fraction absorption models. /Murata K, Tagawa K, Noda K, Samejima M. //J Pharm Sci.- 1989.-78(2).-P.154−159.
- Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates. /Usha AN, Mutalik S, Reddy MS, Ranjith AK, et al. //Eur J Pharm Biopharm.-2008.-70(2).P.-674−83.
- Preparation and evaluation of verapamil hydrochloride microcapsules. /Mukherjee B, Mahanti B, Panda P, Mahapatra S. //Am J Ther.- 2005.-12(5).-P.417−424.
- Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series, № 937, 2006.
- Saranadasa H, Krishnamoorthy K. A multivariate test for similarity of two dissolution profiles. /J Biopharm Stat. -2005.-15(2).-P.265−278.
- Sarfraz MK, Rehman NU, Mohsin S. Naproxen release from sustained release matrix system and effect of cellulose derivatives. // Рак J Pharm Sci. -2006.-19(3).-P.251−255.
- Sathe PM, Tsong Y, Shah VP. In-vitro dissolution profile comparison: statistics and analysis, model dependent approach. // Pharm Res. -1996.-13(12).-P.1799−1803.
- Scholz A., Abrahamsson В., Diebold S.M., Kostewicz E., et al. Influence of Hydrodynamics and Particle Size on the Absorption of Felodipine in Labrador. //Pharmaceutical Research. 2002. — Vol. 19. — № 1. — P.42−46.
- Skrdla PJ. A simple model for complex dissolution kinetics: a case study of norfloxacin. //J Pharm Biomed Anal.- 2007.-45(2).-P.251−256.
- Statistical comparison of dissolution curves. /Bartoszynski R, Powers JD, Herderick EE, Pultz JA. //Pharmacol Res.- 2001.-43(4).-P.369−387.
- Strauch S, Jantratid E, Dressman JB. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hy-clate drug products. //J.Pharm.Pharmacol.-2009.-61(3).-P.331−337.
- Tablet disintegration and drug dissolution in viscous media: paracetamol IR tablets. /Parojcic J, Vasiljevic D, Ibric S, Djuric Z. //Int J Pharm. -2008.-355(l-2).-P.93−99.
- Tamilvanan S, Sa B. In vitro and in vivo evaluation of single-unit commercial conventional tablet and sustained-release capsules compared with multiple-unit polystyrene microparticle dosage forms of Ibuprofen. //AAPS PharmSciTech. -2006.-7(3).-P.72.
- The effect of controlled release tablet performance and hydrogel strength onin vitro/in vivo correlation. /Roshdy MN, Schnaare RL, Sugita ET, Schwartz JB. //Pharm Dev Technol.- 2002.-7(2).-155−168.
- The effect of polyion complex formation on in vitro/in vivo correlation of hydrophilic matrix tablets. /Miyazaki Y, Yakou S, Nagai T, Takayama K. //J Control Release. -2003.-91(3).-P.315−326.
- The influence of formulation on the dissolution profile of diclofenac sodium tablets. /De Castro WV, Pires MA, Oliveira MA, Vianna-Soares CD, e t al. //Drug Dev Ind Pharm. -2006.-32(9).-P.l 103−1109.
- The United States Pharmacopeia, 30th revision, 2007.
- Thurmann P, Bacracheva N. The bioequivalence of two nifedipine fluid capsules. //Arzneimittelforschung.- 1989.-39(12).-P.1597−1599.
- Tulain U, Ur-Rahman N. Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets. //Рак J Pharm Sci.- 2008.-21(2).-P.131−138.
- Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. /Lue BM, Nielsen FS, Magnussen T, et al. //Eur J Pharm Biopharm.- 2008.-69(2).-P.648−657.
- Varshosaz J, Faghihian H, Rastgoo K. Preparation and characterization of metoprolol controlled-release solid dispersions. //Drug Deliv. -2006.-13(4).-P.295−302.
- Vranic E, Mehmedagic A, Hadzovic S. Mathematical methods for quantification and comparison of dissolution testing data. //Bosn J Basic Med Sci.-2002.-2(1−2).-P.49−52.
- Wilson WI, Peng Y, Augsburger LL. Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs. //J Pharm Sci.-2005.-94(12).-P.2764−2776.
- Yau MK, Meyer MC. In vivo-in vitro correlations with a commercial dissolution simulator. I: Methenamine, nitrofurantoin, and chlorothiazide. //J Pharm Sci.-l 981 .-70(9).-1017−1024.
- Yau MK, Meyer MC. In vivo-in vitro correlations with a commercial dissolution simulator II: papaverine, phenytoin, and sulfisoxazole. //J Pharm Sci.-1983 .-72(6).-P.681 -686.
- Zhang X, Tang X, Yang R. Development of a tamsulosin hydrochloride con-trolled-release capsule consisting of two different coated pellets. //Drug Dev Ind Pharm. -2009.-35(l).-P.26−33.